| Dacarbazine |
250 mg/m2 i.v., days 1–5 every 3–4 weeks or |
12.1–17.6% |
|
800–1200 mg/m2 i.v., day 1 every 3-4 weeks |
5.3–23% |
| Temolozomide |
150–200 mg/m2 oral, days 1–5 every 4 weeks |
13.5–21% |
| Fotemustine |
100 mg/m2 i.v. days 1, 8, and 15, followed by 5 week interval, to be repeated every 3 weeks |
7.4–24.2% |
| Vindesine |
3 mg/m2 i.v. every 14 days |
12–26% |
| Interferon alpha |
9m–18m IU/m2 s.c. 3×/week continuous administration |
13–25% |
| Interleukin-2 |
600 000 IU/kg as 15 minute short infusion i.v. every 8 hours on days 1–5 (maximum 14 individual doses), repeat cycle day 14 |
16–21.6% |
